150+ doctors have already invested
Invest in a Faster, Less Painful Dental Anesthetic in a $2.2 B Annual Market
- Less painful, faster-acting, more reliable5
- Patented cartridge technology7
- Same safety profile, same 24-month shelf life
- Seamless replacement: No new equipment, training, or protocols required
The Market
$2.2 Billion Annual Market Opportunity6
* Represents dental anesthetic market only, does not include additional medical vial markets (e.g. dermatology, plastic surgery)
744 Million Units per Year in Serviceable Available Markets
Current usage in our targeted dental markets—North America, Western Europe, Japan, and South Korea—is 744 million units. Total worldwide is 1.9 billion units1.
$220 Million Estimated Revenue for Each 10% of Market Share
BPI has a target average wholesale price of ~$4.00 (est.) per cartridge.
Additional Medical Market Potential
BPI’s patent-pending medical vial technology7 may allow later entry into dermatology, plastic surgery, emergency medicine, interventional radiology, and podiatry markets10.
The Research
Strong Positive Reaction from Dentists
See what dentists (our end users) think about our patent-protected technology7,8 and having pH-balanced anesthetic available to use immediately for their patients (e.g. no manual mixing)
A pH-balanced anesthetic in a standard dental cartridge will be a game changer.
- Jason Goodchild, DMD
Dr. Goodchild holds academic appointments at the University of Pennsylvania School of Dental Medicine, Rutgers School of Dental Medicine, and Creighton University School of Dentistry. He has authored more than 50 research papers on the subject of dental pain management.
A pH-balanced anesthetic in a standard dental cartridge will be a game changer.
- Jason Goodchild, DMD
Dr. Goodchild holds academic appointments at the University of Pennsylvania School of Dental Medicine, Rutgers School of Dental Medicine, and Creighton University School of Dentistry. He has authored more than 50 research papers on the subject of dental pain management.
The innovative cartridges and their contents answer the pharmacological challenges with such elegance.
- Arthur DiMarco, DMD
Dr. DiMarco is the co-author of Local Anesthesia for Dental Professionals,a leading textbook for dental programs. He is a professor at Eastern Washington University.
Company News
Balanced Pharma Announces the First 75 Members of its Clinical Advisory Board
Balanced Pharma's Clinical Advisory Board includes practicing clinicians across multiple specialties that use local anesthetic, including dentistry, dermatology, interventional radiology, plastic surgery, and emergency medicine.
A Problem Worth Solving
Dental Injections are Unnecessarily
Painful, Slow-Acting, and Unreliable
More than half of patients think the injection is the worst part of the dental experience. 90% of dentists want an improved dental anesthetic2,3.
Each Year, Patients Suffer Nearly 2 Billion Dental Injections
- The acid preservative in local anesthetic drugs causes pain during injection and a delayed anesthetic effect.
- Local anesthetic pH can be 25,000 times more acidic than human tissue.
- For dentists, this means uncomfortable patients, wasted time, and wasted money.
Painful injection
Long wait time
20% avg. failure rate
Time & money wasted
The Solution
The First and Only pH-Balanced
Dental Anesthetic
Our patent-protected technology7 can deliver a less painful, faster-acting, and more reliable5 dental anesthetic with the convenience of the equipment clinicians already use and trust.
Introducing Libracaine® Dental9
The First and Only pH-Balanced Dental Anesthetic
The Convenience of a Standard Dental Cartridge
- Less painful, faster-acting, more reliable5
- Patented cartridge technology7
- 505(b)(2) abbreviated FDA regulatory pathway
- A pH-balanced version of the most often-used anesthetic in dentistry4
The Technology
Our Patent-Protected Libracaine® Cartridge
Because Libracaine will be supplied in a standard dental cartridge, dentists can seamlessly replace their current anesthetic with the new pH-balanced Libracaine Dental anesthetic9.
- Less painful, faster-acting, more reliable5
- Patented cartridge technology7
- Same safety profile, same 24-month shelf life
- No new equipment, training, or protocols required
Founder's Story
A Dentist on a Mission to Improve Patient Comfort
"We want to provide the best possible experience for patients."
- Scott Keadle, DDS | CEO, Balanced Pharma
Meeting the Need for Less Painful, Faster-Acting Dental Injections
Dr. Scott Keadle, a dentist for over 30 years, experienced firsthand the limitations of current dental anesthetic drugs and their inability to provide a fast-acting, reliable, and painless injection.
He wanted a better anesthetic for his patients: Less injection pain, less waiting time, and more reliability.
A New Anesthetic. Created for Clinicians, by Clinicians.
Dr. Keadle invented patented technology7 to enable pH-balanced versions of the most common local anesthetics, using a standard syringe and protocol. He then presented the opportunity to a group of dentists who invested over $1 million to help found Balanced Pharma Incorporated (BPI).
Now he leads a team of industry experts who are committed to bringing the first-ever pH-balanced dental anesthetic to market.
Invest in a Faster, Less Painful Dental Anesthetic
Balanced Pharma is pioneering the movement toward less painful, faster-acting, more reliable dental injections.
Become an investor today!
The Team
Balanced Pharma Team
Our growing team is dedicated to excellence in our mission to improve patient comfort.
John S. Keadle, DDS
Founder and CEO at Balanced Pharma, 30+ years as a dentist, practice owner and business executive
John Selig
Managing Partner at WaveEdge Capital, 25+ years in life science investment banking and M&A practice
Mark Sebree
Chief Development Officer
Former CEO, Becton Dickinson Rx; 35+ years in strategy, acquisitions, and operations in the pharma industry
Eric Sherb
13 years experience in accounting advisory, auditing, and M&A; extensive experience in financial reporting
Jason Suggs
CEO at Orange Reef, 20+ years in brand strategy, communications, and technology
Nita U. Patel, Ph.D.
SVP, Global Reg. Issues and Head of CMC, at ProPharma Group; 30+ years of R&D and pharmaceutical industry experience
Steve Jensen
EVP, Head of U.S. Regulatory Sciences, at ProPharma Group; 22+ years of pharmaceutical industry experience
Alex Sadusky
CEO, TruBlu Dental; Former Dentsply Sirona Senior Executive; Former Senior External Advisor, McKinsey & Co. Pharma & Med Products Division
Sara Hanks, Esq.
CEO, CrowdCheck Law Firm
Byron Kirkland, Esq.
Managing Partner, Smith Anderson Law Firm
Scientific Advisory Board
Bishr Al-Dabagh, MD, MBA, FAAD, FACMS
Board-certified dermatologist (American Board of Dermatology), fellowship-trained dermatologic surgeon (American College of Mohs Surgery), and a fellow of the American Academy of Dermatology (AAD). Dr. Al-Dabagh has published over 20 peer-reviewed articles and book chapters.
Larina Chu, DDS, M-PA, CLS
Dentist anesthesiologist serving the greater Hesperia, California area. Dr. Chu is a professional member of the American Board of Dental Anesthesiologists, the American Dental Association, the California Dental Association and the Tri-County Dental Society.
Mark Donaldson, Pharm.D.
Associate Principal at Vizient Pharmacy Advisory Solutions, 17+ years as a recognized expert in dental pharmacology, He holds academic appointments at the University of Montana and the Oregon Health & Sciences University and serves on the editorial board of the Journal of the American Dental Association.
Jay B. Reznick, DMD, MD
Director of the Southern California Center for Oral and Facial Surgery in Tarzana, California; Diplomate of the American Board of Oral and Maxillofacial Surgery; the first specialist in the U.S. to integrate CBCT and CAD/CAM in his practice; has been published extensively in dental and medical literature
John B. Roberson, DMD
Oral & Maxillofacial Surgeon; CEO and Co-Founder of AAFDO (Accreditation Association For Dental Offices); CEO and Co-founder. of the Institute of Medical Emergency Preparedness; author and lecturer; selected as a CE Leader for Dentistry Today for 10 consecutive years.
Clinical Advisory Board
Balanced Pharma’s Clinical Advisory Board includes over 75 practicing clinicians across multiple specialties that use local anesthetic.
Mamta Patel
Dentist; Owner, Stamford Dental Spa; University of Connecticut; Licensed in CT, NY
Marcus Johnson
Endodontist; Lecturer, Teacher, Interfaith Hospital; NYU Dental School
Wenhong Peng
Dentist; Owner, Peng Dental Health; Harvard School of Public Health
Elaine Vowell
Dentist; Founder, Your Best Shot; Creighton University School of Dentistry
Gildo Corradi
Dentist; Owner, Midtown Manhattan Dental Arts; Lecturer, Anesthesia; Residency, Mount Sinai
Nawaf Aslam-Pervez
Oral & Maxillofacial Surgeon; Former Assistant Professor, Department of Surgery, Mayo Clinic; Trinity College of Dublin, Royal College of Surgeons
Traci McCormick
Radiation Oncologist; CEO and Medical Director, Precision MD Wellness; Residency, Indiana University
Robert Chen
Emergency Physician; Medical Director; St. Louis University
Ethan Chase
Dentist; Clinical Lecturer, Boston University Goldman School of Dental Medicine
Pedram Mastour
Dentist; Clinical Assistant Professor, Division IV, The Herman Ostrow School of Dentistry, USC
Nancy Dulin
Anesthesiologist; University of Alabama School of Medicine; Wake Forest Baptist Medical Center
Samer Elbatanouny
Dentist; Mastership, International Dental Implant Association
View additional members of the Clinical Advisory Board at BalancedPharma.com.
THIS WEBSITE MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.
(1) “58% OF PATIENTS BELIEVE THE INJECTION IS THE WORST PART OF THE DENTAL EXPERIENCE,” OLSON RESEARCH GROUP, “PATIENT DENTAL CARE STUDY QUANTITATIVE REPORT, CONDUCTED FOR BALANCED PHARMA, MAY 7, 2021,” FIELDING: MARCH 30–APRIL 23, 2021, TOTAL SAMPLE SIZE: N=140 (INCLUDES 40 PARENTS/CAREGIVERS)
(2) “WHAT PATIENTS WANT: A LESS-PAINFUL DENTAL INJECTION: 86%,” OLSON RESEARCH GROUP, “PATIENT DENTAL CARE STUDY QUANTITATIVE REPORT, CONDUCTED FOR BALANCED PHARMA, MAY 7, 2021,” FIELDING: MARCH 30–APRIL 23, 2021, TOTAL SAMPLE SIZE: N=140 (INCLUDES 40 PARENTS/CAREGIVERS)
(3) “OVER 90% OF DENTISTS REPORT A DESIRE FOR CURRENT ANESTHETICS TO BE MORE RELIABLE, LESS PAINFUL, OR FASTER ACTING,” OLSON RESEARCH GROUP, “DENTIST QUANTITATIVE REPORT, CONDUCTED FOR BALANCED PHARMA, AUGUST 13, 2021,” FIELDING: JUNE 18–JULY 19, 2021, TOTAL SAMPLE SIZE: N=181;
(4) “DENTISTS REPORT AN INITIAL ANESTHETIC FAILURE RATE OF 20%,” OLSON RESEARCH GROUP, “DENTIST QUANTITATIVE REPORT, CONDUCTED FOR BALANCED PHARMA, AUGUST 13, 2021,” FIELDING: JUNE 18–JULY 19, 2021, TOTAL SAMPLE SIZE: N=181
(5) 2018 META-ANALYSIS: SIGNIFICANTLY DECREASED ONSET TIME AND INJECTION PAIN; GUO ET AL FROM UNIVERSITY OF SOUTHERN CALIFORNIA SCHOOL OF DENTISTRY CONCLUDED: “BUFFERED LIDOCAINE SIGNIFICANTLY DECREASED ONSET TIME AND INJECTION PAIN (VAS) COMPARED WITH NON-BUFFERED LIDOCAINE IN INFERIOR ALVEOLAR NERVE BLOCK.”; 2017 CLINICAL STUDY: REDUCES THE PAIN ON INJECTION; PHERO ET AL FROM UNIVERSITY OF NORTH CAROLINA SCHOOL OF DENTISTRY CONCLUDED: “BUFFERED LIDOCAINE REDUCES THE PAIN ON INJECTION WITH A MAXILLARY FIELD BLOCK AND RESULTS IN SIMILAR LENGTHS OF PULPAL ANESTHESIA AS NON-BUFFERED 2% LIDOCAINE.” 2017 CLINICAL STUDY: LOWER PAIN ON INJECTIONS. WARREN ET AL FROM UNIVERSITY OF NORTH CAROLINA SCHOOL OF DENTISTRY CONCLUDED: “AFTER MANDIBULAR NERVE BLOCK, BUFFERED 1% LIDOCAINE CAN PRODUCE SIMILAR DURATION OF PULPAL ANESTHESIA AS NON-BUFFERED 2% LIDOCAINE AND LOWER PAIN ON INJECTIONS.”; 2019 META-ANALYSIS: 2.29 TIMES MORE RELIABLE IN INFLAMED TEETH; KATTAN ET AL FROM UNIVERSITY OF PENNSYLVANIA SCHOOL OF DENTISTRY CONCLUDED: “BUFFERED LOCAL ANESTHETICS HAVE 2.29 TIMES GREATER LIKELIHOOD OF ACHIEVING SUCCESSFUL ANESTHESIA [IN PULPALLY INVOLVED TEETH].”
(6) SDM NORTHCOAST, LLC REPORT, “INJECTABLE CARPULES MARKET SIZE ANALYSIS, UNITED STATES, CANADA, MEXICO, 2019 UNITS”, JULY 15, 2021; KEY-STONE RESEARCH, “EUROPEAN LOCAL ANESTHETICS MARKET SURVEY,” SEPTEMBER 20, 2021; BALANCED PHARMA INTERNAL ESTIMATES
(7) BPI OWNS THE FOLLOWING GRANTED PATENTS AND PENDING PATENT APPLICATIONS: U.S. PATENT NO. 11,305,064 (ISSUED APRIL 19TH, 2022); U.S. APPLICATION NO. 17/722,016; INTERNATIONAL PCT APPLICATION NO. PCT/IB2018/052598; CANADIAN APPLICATION NO. 3,111,347 (CANADIAN NATIONAL PHASE OF PCT/IB2018/052598); EUROPEAN APPLICATION NO. 18897951.2 (EUROPEAN REGIONAL PHASE OF PCT/IB2018/052598); JAPANESE APPLICATION NO. 2020-556351 (JAPANESE NATIONAL PHASE OF PCT/IB2018/052598); KOREAN APPLICATION NO. 10-2020-7021685 (REPUBLIC OF KOREA NATIONAL PHASE OF PCT/IB2018/052598); U.S. APPLICATION NO. 16/655,362; U.S. APPLICATION NO. 63/233,879; BPI ALSO OWNS ONE TRADEMARK APPLICATION, U.S. APPLICATION NO. 88/198,808, PENDING FOR THE LIBRACAINE MARK.
(8) OLSON RESEARCH GROUP, “U.S. DENTIST QUANTITATIVE REPORT, CONDUCTED FOR BALANCED PHARMA, AUGUST 13TH, 2021,” TOTA SAMPLE SIZE: 181 DENTISTS; KEY-STONE RESEARCH, “EUROPEAN LOCAL ANESTHETICS MARKET SURVEY, CONDUCTED FOR BALANCED PHARMA, SEPTEMBER 20, 2021,” TOTAL SAMPLE SIZE: 433 DENTISTS
(9) LIBRACAINE HAS NOT YET BEEN APPROVED BY FDA AND IS NOT AVAILABLE FOR SALE.
(10) BPI HAS NOT YET BEGUN TRIALS TO DETERMINE WHETHER ITS TECHNOLOGY CAN ADAPT TO DERMATOLOGY, PLASTIC SURGERY, EMERGENCY MEDICINE, INTERVENTIONAL RADIOLOGY, AND PODIATRY.
Balanced Pharma, Inc.
18204 Mainsail Pointe
Cornelius, NC 28031
investor@balancedpharma.com
(980) 939-7573
Balanced Pharma, Inc.
18204 Mainsail Pointe
Cornelius, NC 28031
investor@balancedpharma.com
(980) 939-7573
Copyright 2023 Balanced Pharma, Inc. ™